Clik here to view.
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to...
Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions. VICTORIA, BC & ROCKVILLE, MD.– Aurinia Pharmaceuticals Inc....
View ArticleAurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached...
Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 Parties have settled the patent infringement claim against Sun’s CEQUA® product...
View ArticleAurinia Pharmaceuticals Announces Presentations at American Society of...
EDMONTON, AB — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune...
View ArticleCorrecting and Replacing Aurinia Pharmaceuticals to Release Third Quarter...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023,...
View ArticleAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net...
Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and...
View Article
